Exploring the Safety Profile of Ornidazole as Drug Candidate for Endometriosis Treatment

Gynecol Obstet Invest. 2023;88(3):185-186. doi: 10.1159/000530461. Epub 2023 Apr 4.

Authors

Fabio Barra^{1

2}, Umberto Perrone^{1

3}, Angela Iasci¹, Simone Ferrero^{3

4}, Stefano Bogliolo¹

Affiliations

¹ Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy.
² Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy.
³ Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.
⁴ Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

PMID: 37015203
DOI: 10.1159/000530461

No abstract available

Publication types

Letter
Comment

MeSH terms

Endometriosis* / drug therapy
Female
Humans
Ornidazole* / adverse effects

Substances

Ornidazole